Phillip A. Dennis
Affiliations: | National Cancer Institue-NIH |
Google:
"Phillip Dennis"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chang YS, Gills JJ, Kawabata S, et al. (2023) Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia. International Journal of Oncology. 63 |
| Ouwens M, Darilay A, Zhang Y, et al. (2021) Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study. Current Therapeutic Research, Clinical and Experimental. 95: 100640 |
| Socinski MA, Özgüroğlu M, Villegas A, et al. (2021) Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). Clinical Lung Cancer |
| Kawabata S, Connis N, Gills JJ, et al. (2021) Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. Anticancer Research. 41: 91-99 |
| Lopiccolo J, Kawabata S, Gills JJ, et al. (2021) Combining Nelfinavir With Chloroquine Inhibits Growth of Human Lung Cancer Xenograft Tumors. In Vivo (Athens, Greece). 35: 141-145 |
| Hui R, Özgüroğlu M, Villegas A, et al. (2019) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. The Lancet. Oncology |
| Komiya T, Memmott RM, Blumenthal GM, et al. (2019) A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. Translational Lung Cancer Research. 8: 247-257 |
| Sridhar S, Paz-Ares L, Liu H, et al. (2019) Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clinical Lung Cancer |
| Raben D, Rimner A, Senan S, et al. (2019) Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC) International Journal of Radiation Oncology*Biology*Physics. 105: 683 |
| Antonia SJ, Villegas A, Daniel D, et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England Journal of Medicine |